Skip to main content
Premium Trial:

Request an Annual Quote

Precision Oncology Resources: Webinars

Tue
Apr
23
12:00 PM
US Eastern

Sponsored by Porex Filtration Group

Redefining Conventional Diagnostics: Adapting Materials for Integrated Biochemical Analysis to Increase Access to Testing

Unlocking the full potential of diagnostics requires rethinking traditional sample collection and preparation. Standard procedures rely on pipetting known volumes, prepping reagents, and performing multi-step purification in a laboratory setting. Each step requires experience and specialized equipment. Many point-of-care devices miniaturize and automate protocols, to bring results closer to users and speed up diagnosis. However, these procedures can be simplified even further by utilizing innovative techniques in materials, treatment, and overall design.

In this webinar, Ben Cobb, founder of ReadyGo Diagnostics, will explore the intersection of material science and biochemical analysis, offering an innovative approach in the field of diagnostics. The session will explore the integration of Porex materials with ReadyGo’s chemistry and design platforms, which have simplified measured laboratory procedures — like pipetting and cell lysis prep — into cost-effective workflows suitable for any user. In doing so, they address preanalytical challenges and enable greater access to testing.

Sponsored by

Porex_logo_300ppi.jpg
Tue
Apr
23
1:00 PM
US Eastern

Sponsored by Nucleai

Spatial AI Biomarkers: Expanding the Eligible Patient Pool With Novel Histopathology Signatures

Advancing the development of next-gen cancer treatments like antibody-drug conjugates (ADCs), bispecific antibodies, and immunotherapy requires the analysis of complex patterns hidden in a patient’s tissue biopsy and drawing clinically relevant biomarker signatures that can predict treatment response. Novel artificial intelligence (AI) algorithms, based on advancements in military intelligence-grade geospatial analysis, are providing the ability to analyze all this biological complexity in an automated, precise, and scalable fashion, accelerating the development of novel therapeutics.

 In this webinar, the speakers will share:

  • How AI-driven spatial biomarker analysis can extract predictive signatures across multiple pathology modalities such as H&E-stained slides, immunohistochemistry (IHC), multiplex immunofluorescence (mIF i.e., spatial proteomics), and spatial transcriptomics.
  • The applications of spatial AI analysis for mechanism-of-action (MoA) studies, optimizing biomarker scoring, predicting treatment response, and determining biomarker prevalence.
  • A case study on how novel spatial features, including tumor-infiltrating lymphocytes (TILs), are correlated to outcomes in squamous cell carcinoma of the head and neck (SCCHN), and can be easily extracted from broadly accessible H&E slides, with the potential to expand patient access to lifesaving treatments.

Sponsored by

logo-3000px.png
Tue
May
07
1:00 PM
US Eastern

Immunotherapy Frontiers: Cellular Therapies and Biomarker Discordance in Solid Tumors

This webinar is part one of the two-part Precision Oncology News Virtual Molecular Tumor Board series.

The approval of tumor-infiltrating lymphocytes (TILs) marks a significant advancement in cellular therapies for solid tumors, heralding a new chapter in immunotherapy. 

This presentation will explore the nuanced decision-making process in immunotherapy selection, comparing the roles of microsatellite instability (MSI)/mismatch repair (MMR) status versus PD-L1 expression versus high tumor mutational burden (TMB), and addressing the challenges of discordant results between immunohistochemistry (IHC) for mismatch repair proteins and microsatellite instability testing. Through these insights, we aim to illuminate the path forward in harnessing immunotherapy's full potential for solid tumors.

Thu
May
16
1:00 PM
US Eastern

Navigating the Complexities and Controversies of Integrative Molecular Strategies in Oncology

This webinar is part two of the two-part Precision Oncology News Virtual Molecular Tumor Board series.

The advent of precision oncology has transformed the therapeutic landscape for patients, presenting a paradigm shift from one-size-fits-all approaches to individualized treatment strategies. 

This presentation will recognize the intricate balance between the potential of various assays to guide treatment decisions and the controversies surrounding their interpretation and clinical utility. Our panelists will highlight the critical importance of Variant Allele Frequency (VAF) as a biomarker for tumor burden and treatment response, as well as explore the burgeoning field of Molecular Residual Disease (MRD) assays with a focused lens on their application in solid tumors. In addition, the concurrent application of tissue-based and liquid-based Next-Generation Sequencing (NGS) testing represents a cornerstone in the evolution of diagnostic modalities. By weaving together the threads of sequencing, VAF, and MRD assays, our presentation aims to feature the synergy of these technologies in advancing precision oncology, while acknowledging the challenges and debates that shape this dynamic field.

Thu
May
30
1:00 PM
US Eastern

Sponsored by SomaLogic

Predictive Modeling and Reliable Biomarker Discovery in Clinical Omics Studies

High-content omics technologies coupled with machine-learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features.

In this webinar, drawing examples from real-world clinical omics studies, Julien Hédou will introduce Stabl, a general machine-learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.

Sponsored by

Tue
Jun
25
11:30 AM
US Eastern

Multiomics in Precision Medicine

This event, part of the Precision Medicine Leaders’ Summit conference series and developed in partnership with the University of Pennsylvania Institute for Biomedical Informatics, will explore how multiomics methods are advancing precision medicine in a range of human disease areas.

Recent advances in multiomic approaches — including genomics, transcriptomics, epigenomics, proteomics, and metabolomics — enable a more comprehensive picture of disease biology. This promises to accelerate the development of precision medicine, but also presents challenges for researchers, clinicians, and health systems struggling to integrate disparate data sources into a cohesive clinical strategy.

Multiomics in Precision Medicine 2024 will highlight best practices, trends, and strategies from experts who are successfully implementing a range of omics approaches to advance molecularly informed medicine.

Thu
Sep
19
11:00 AM
US Eastern

Advances in Single Cell and Spatial Biology

Learn how single-cell genomics and spatial biology are poised to advance precision medicine at PMLS Advances in Single Cell and Spatial Biology, to be held September 19 – 20, 2024, in San Diego. 

Single-cell and spatial omics technologies have provided unprecedented insights into tissue heterogeneity and biological complexity, driving new opportunities in genomic medicine. These complementary approaches have converged in recent years to create a new toolkit of methods to explore the spatial position of molecular features in a cell or tissue. 

While single-cell RNA-sequencing experiments map transcripts to individual cells, the positions of these transcripts within the tissue are not always known. And spatial transcriptomics can elucidate the location of transcripts but not always the cell that produced them. Studies using these techniques alone or in combination are producing a wealth of data to advance the fields of developmental biology, cancer, immunology, and neuroscience.

Join us to hear important insights from pioneers in single-cell and spatial omics. This two-day event, part of the 2024 Precision Medicine Leaders’ Summit series, will feature high-level discussions and ample networking opportunities with experts from key research organizations, cancer institutes, pathology labs, technology developers, and pharmaceutical executives who are driving innovation in the field and advancing the implementation of these methods into patient care.

Tue
Oct
15
9:00 AM
US Eastern

Precision Oncology & Diagnostics

This event, developed with guidance from the editorial team of Precision Oncology News, will focus on the rapidly evolving field of precision oncology, including new diagnostic and therapeutic modalities, regulatory and reimbursement trends, and implementation challenges.

PMLS Precision Oncology and Diagnostics 2024 will bring together key stakeholders to discuss strategies and best practices for implementing molecularly guided cancer care. Thought leaders from pharmaceutical and biotech firms, leading cancer centers, and the research community will share real-world experiences in delivering precision oncology to patient populations.

Anyone tracking the opportunities and challenges associated with individualized cancer therapy will want to attend this event, including oncologists, pathologists, health system executives, regulatory and reimbursement experts, clinical researchers, and pharmaceutical/biotech executives.